Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. It offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch Glucose Monitoring System for Dogs and Cats. The company also prov… Read more
Bioptik Technology (4161) - Total Assets
Latest total assets as of September 2025: NT$1.46 Billion TWD
Based on the latest financial reports, Bioptik Technology (4161) holds total assets worth NT$1.46 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioptik Technology - Total Assets Trend (2017–2024)
This chart illustrates how Bioptik Technology’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bioptik Technology - Asset Composition Analysis
Current Asset Composition (December 2024)
Bioptik Technology's total assets of NT$1.46 Billion consist of 58.1% current assets and 41.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 25.6% |
| Accounts Receivable | NT$43.14 Million | 2.9% |
| Inventory | NT$205.41 Million | 13.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Bioptik Technology's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioptik Technology's current assets represent 58.1% of total assets in 2024, a decrease from 59.2% in 2017.
- Cash Position: Cash and equivalents constituted 25.6% of total assets in 2024, up from 25.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 13.8% of total assets.
Bioptik Technology Competitors by Total Assets
Key competitors of Bioptik Technology based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Bioptik Technology - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Bioptik Technology generates 0.58x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Bioptik Technology generates $6.29 in net profit.
Bioptik Technology - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 1.80 | 1.56 |
| Quick Ratio | 1.56 | 1.35 | 1.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$423.08 Million | NT$ 384.96 Million | NT$ 268.67 Million |
Bioptik Technology - Advanced Valuation Insights
This section examines the relationship between Bioptik Technology's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.59 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | NT$1.49 Billion |
| Market Capitalization | $30.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioptik Technology's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bioptik Technology's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bioptik Technology (2017–2024)
The table below shows the annual total assets of Bioptik Technology from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.49 Billion | -0.67% |
| 2023-12-31 | NT$1.50 Billion | -1.16% |
| 2022-12-31 | NT$1.52 Billion | -0.57% |
| 2021-12-31 | NT$1.52 Billion | +3.40% |
| 2020-12-31 | NT$1.47 Billion | -5.19% |
| 2019-12-31 | NT$1.55 Billion | -3.08% |
| 2018-12-31 | NT$1.60 Billion | +2.45% |
| 2017-12-31 | NT$1.57 Billion | -- |